psychedelic-assisted therapy

House members recently approved the Senate measure, that seeks to set up an eight-person psychedelic-assisted therapy working group, with amendments. Vermont Senators gave the green light to the revised language of the bill on Friday, approving changes previously made in the state House of...

The National Institutes of Health (NIH) recently said it will fund clinical trials to exam the safety and efficacy of psychedelic-assisted therapy in older adults with chronic pain, reported Marijuana Moment. According to NIH's Wednesday notice, it intends to direct $8.4 million toward research on...

The TDR Three Takeaways: Numinus Wellness Inc. partners with Eight Capital in a $6 million bought deal, involving the purchase of 50,000,000 units, strengthening the company’s financial position for future mental health initiatives. The involvement of MAPS and Integrated V.C. in Numinus...

Jada Pinkett Smith has joined the growing number of Hollywood celebs who are sharing difficult mental health issues and the fact that psychedelic substances are helping them deal with them. “Ayahuasca helped me. It gave me a new, intimate relationship with...

This article was originally published on Microdose and appears here with permission. Psychedelic culture has a long and rich history. It has influenced music, art, and spirituality in profound ways. In recent years, there has been a resurgence of interest in psychedelics, and there is a growing...

As professional athletes continue to endorse psychedelic-assisted therapy, former Colorado Avalanche defenseman Kyle Quincey is taking it to the next level. He recently announced the building of a psilocybin-assisted therapy center in the state where voters approved the...

Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this: Cash and cash equivalents totaled $116.9 million, a 17.8% six-month decrease from the $142.1 million held in Dec. 31, 2022, and yet believed to be...

Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows: Cash and cash equivalents totaled $148.2 million, compared to $143.2 million held in Dec. 31, 2022, and considering this 2023...

Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries The agency regulating all things related to psychedelic-assisted therapy (PAT), Health Canada released a notice to stakeholders on risk-management measures for clinical trials, a...

(Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes COMPASS (NASDAQ: CMPS)’ Phase 2 trial published results elicited several comments from experts in the field as well as...